ATE410518T1 - Kompaktnukleinsäure und ihre verabreichung in zellen - Google Patents

Kompaktnukleinsäure und ihre verabreichung in zellen

Info

Publication number
ATE410518T1
ATE410518T1 AT95914173T AT95914173T ATE410518T1 AT E410518 T1 ATE410518 T1 AT E410518T1 AT 95914173 T AT95914173 T AT 95914173T AT 95914173 T AT95914173 T AT 95914173T AT E410518 T1 ATE410518 T1 AT E410518T1
Authority
AT
Austria
Prior art keywords
nucleic acid
nucleic acids
cells
compacted
administration
Prior art date
Application number
AT95914173T
Other languages
English (en)
Inventor
Richard W Hanson
Jose C Perales
Thomas W Ferkol
Original Assignee
Univ Ohio
Univ Case Western Reserve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio, Univ Case Western Reserve filed Critical Univ Ohio
Application granted granted Critical
Publication of ATE410518T1 publication Critical patent/ATE410518T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
AT95914173T 1994-03-23 1995-03-23 Kompaktnukleinsäure und ihre verabreichung in zellen ATE410518T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21653494A 1994-03-23 1994-03-23

Publications (1)

Publication Number Publication Date
ATE410518T1 true ATE410518T1 (de) 2008-10-15

Family

ID=22807432

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914173T ATE410518T1 (de) 1994-03-23 1995-03-23 Kompaktnukleinsäure und ihre verabreichung in zellen

Country Status (9)

Country Link
US (3) US5877302A (de)
EP (1) EP0752005B1 (de)
JP (2) JP4285766B2 (de)
AT (1) ATE410518T1 (de)
AU (1) AU696455C (de)
CA (1) CA2186118C (de)
DE (1) DE69535853D1 (de)
ES (1) ES2316148T3 (de)
WO (1) WO1995025809A1 (de)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5218704A (en) * 1989-10-30 1993-06-08 Texas Instruments Real-time power conservation for portable computers
JP4285766B2 (ja) * 1994-03-23 2009-06-24 オハイオ ユニバーシティ 緻密にした核酸および細胞へのデリバリ
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US5994316A (en) * 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6258792B1 (en) 1996-04-12 2001-07-10 University Of Pittsburgh Cationic cholesteryl derivatives containing cyclic polar groups
ES2165050T3 (es) * 1996-04-12 2002-03-01 Univ Pittsburgh Nuevos derivados cationicos de colesterilo que contienen grupos polares ciclicos.
WO1998000110A1 (en) * 1996-07-03 1998-01-08 University Of Pittsburgh Emulsion formulations for hydrophilic active agents
DE69732710T2 (de) * 1996-10-09 2005-07-28 Oxford Biomedica (Uk) Ltd. Mononukleare phagozyten zur verabreichung von therapeutischen arzneimitteln
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6894031B1 (en) * 1996-11-21 2005-05-17 Cedars-Sinai Medical Center Pituitary tumor transforming gene (PTTG) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation
US6913926B2 (en) * 1996-11-21 2005-07-05 Cedars-Sinai Medical Center Method of regulating biological activity of pituitary tumor transforming gene (PTTG)1 using PTTG2
US7097829B2 (en) * 1996-11-21 2006-08-29 Cedars-Sinai Medical Center Transgenic cells transfected with pituitary tumor transforming gene (PTTG)) expression vectors and uses therefor
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
EP1054694A2 (de) 1998-02-13 2000-11-29 Selective Genetics, Inc. Gleichzeitige strömungsdurchmischung zur herstellung von zusammensetzungen, die gentherapievektoren enthalten
DE19858005B4 (de) * 1998-12-16 2007-02-08 november Aktiengesellschaft, Gesellschaft für Molekulare Medizin Synthetisches Nucleinsäure-Partikel
EP2368575B1 (de) * 1999-04-08 2014-10-01 Intercell USA, Inc. Trockenformulierung für transkutane immunisierung
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US6770740B1 (en) 1999-07-13 2004-08-03 The Regents Of The University Of Michigan Crosslinked DNA condensate compositions and gene delivery methods
MXPA02009449A (es) * 2000-03-27 2003-09-22 Univ California Ligandos dirigidos a la region no del eje del componente no secretor de la pigr y metodos de uso de los mismos.
US20020042388A1 (en) 2001-05-01 2002-04-11 Cooper Mark J. Lyophilizable and enhanced compacted nucleic acids
CA2410265A1 (en) * 2000-05-31 2001-12-06 Copernicus Therapeutics, Inc. Lyophilizable and enhanced compacted nucleic acids
GB0027328D0 (en) * 2000-06-23 2000-12-27 Aventis Pharma Inc Bioengineered vehicles for targeted nucleic acid delivery
US20020081736A1 (en) * 2000-11-03 2002-06-27 Conroy Susan E. Nucleic acid delivery
WO2002042447A2 (en) * 2000-11-03 2002-05-30 Regents Of The University Of Michigan Surface transfection and expression procedure
US6812217B2 (en) 2000-12-04 2004-11-02 Medtronic, Inc. Medical device and methods of use
DE10063112A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Erhöhung der klinischen Spezifität bei der Detektion von Tumoren und ihren Vorstufen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern
WO2002064162A2 (en) * 2001-02-13 2002-08-22 Government Of The United States, As Represented By The Secretary Of The Army Vaccine for transcutaneous immunization
WO2002075306A1 (en) * 2001-03-16 2002-09-26 Large Scale Biology Corporation Episomal non-transforming nucleic acid elements in functional genomic and antigenic applications
US7294511B2 (en) * 2001-03-22 2007-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030203865A1 (en) * 2001-04-30 2003-10-30 Pierrot Harvie Lipid-comprising drug delivery complexes and methods for their production
GB0114719D0 (en) * 2001-06-15 2001-08-08 Glaxo Group Ltd Compound
US6909030B2 (en) 2001-10-15 2005-06-21 Cedars-Sinai Medical Center PTTG knockout rodent as a model to study mechanisms for various physiological phenomena, including diabetes
US20040016013A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US20040014704A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent induces tolerance
AU2003298816C1 (en) * 2002-12-02 2010-12-16 Amgen Fremont, Inc. Antibodies directed to Tumor Necrosis Factor and uses thereof
CA2513072A1 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
CA2515892C (en) 2003-02-14 2012-10-23 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
US20050136437A1 (en) * 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
US20050208032A1 (en) * 2004-01-16 2005-09-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US7358223B2 (en) 2004-10-04 2008-04-15 Nitto Denko Corporation Biodegradable cationic polymers
EP2281889B1 (de) 2004-11-12 2014-07-30 Asuragen, Inc. Verfahren und Zusammensetzungen, die miRNAs und miRNA-inhibitorischen Molekülen verbunden sind
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
US7700541B2 (en) 2006-04-06 2010-04-20 Nitto Denko Corporation Biodegradable cationic polymers
JP5718570B2 (ja) 2006-08-01 2015-05-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ベータミオシン重鎖の発現を活性化するマイクロｒｎａの同定
US20100143372A1 (en) 2006-12-06 2010-06-10 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
DK2591795T3 (en) * 2007-02-23 2018-05-07 Univ New York State Res Found RNA TARGETING COMPOUNDS AND PROCEDURES FOR PREPARING AND USING THE SAME
US9260476B2 (en) 2007-02-23 2016-02-16 The Research Foundation For The State University Of New York RNA targeting compounds and methods for making and using same
WO2008137066A1 (en) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
CA2686861A1 (en) 2007-05-03 2008-11-13 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
CA2692453C (en) 2007-07-12 2018-01-09 Trevor Collingwood Methods and compositions for inactivating alpha 1,6 fucosyltransferase (fut8) gene expression
CA2694930C (en) 2007-07-31 2019-11-12 Board Of Regents, The University Of Texas System A micro-rna family that modulates fibrosis and uses thereof
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
US8051513B2 (en) * 2007-12-31 2011-11-08 Monster Medic, Inc. Ambulance cot system
CN102036689B (zh) 2008-03-17 2014-08-06 得克萨斯系统大学董事会 神经肌肉突触维持和再生中涉及的微小rna的鉴定
CA2726768C (en) 2008-06-10 2016-09-06 Sangamo Biosciences, Inc. Methods and compositions for generation of bax- and bak-deficient cell lines
US8268796B2 (en) 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof
SG191561A1 (en) 2008-08-22 2013-07-31 Sangamo Biosciences Inc Methods and compositions for targeted single-stranded cleavage and targeted integration
CN102625655B (zh) 2008-12-04 2016-07-06 桑格摩生物科学股份有限公司 使用锌指核酸酶在大鼠中进行基因组编辑
US8492133B2 (en) 2009-01-20 2013-07-23 Ramot At Tel Aviv University, Ltd. MIR-21 promoter driven targeted cancer therapy
US8551945B2 (en) 2009-02-04 2013-10-08 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathies
US9834787B2 (en) 2009-04-09 2017-12-05 Sangamo Therapeutics, Inc. Targeted integration into stem cells
EP2960342A1 (de) 2009-04-14 2015-12-30 Nestec S.A. Prognose für entzündliche darmerkrankungen
CA2769262C (en) 2009-07-28 2019-04-30 Sangamo Biosciences, Inc. Methods and compositions for treating trinucleotide repeat disorders
WO2011060098A1 (en) 2009-11-10 2011-05-19 Prometheus Laboratories Inc. Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
US10260062B2 (en) 2010-01-22 2019-04-16 Sangamo Therapeutics, Inc. Targeted genomic alteration
JP2013518602A (ja) 2010-02-09 2013-05-23 サンガモ バイオサイエンシーズ， インコーポレイテッド 部分的に一本鎖のドナー分子による標的化ゲノム改変
EP3214174B1 (de) 2010-03-04 2019-10-16 InteRNA Technologies B.V. Mirna-molekül, das über seine quelle definiert ist, und seine diagnostischen und therapeutischen verwendungen bei mit emt assoziierten krankheiten
CN103025344B (zh) 2010-05-17 2016-06-29 桑格摩生物科学股份有限公司 新型dna-结合蛋白及其用途
EP3369817A1 (de) 2010-07-06 2018-09-05 InteRNA Technologies B.V. Mirna und ihre diagnostischen und therapeutischen verwendungen bei erkrankungen und zuständen im zusammenhang mit melanomen oder bei erkrankungen und zuständen mit einem aktivierten braf-pfad
AU2011312562B2 (en) 2010-09-27 2014-10-09 Sangamo Therapeutics, Inc. Methods and compositions for inhibiting viral entry into cells
WO2012067837A1 (en) * 2010-11-15 2012-05-24 Avon Products, Inc. Biofunctional anchored extended-wear cosmetics
EP2474617A1 (de) 2011-01-11 2012-07-11 InteRNA Technologies BV MIR zur Behandlung von Neoangiogenese
EP2737063B1 (de) 2011-07-25 2016-06-01 Sangamo BioSciences, Inc. Verfahren und zusammensetzungen zur änderung eines zystenfibrose-transmembran-leitungsregulator-gens
KR102061557B1 (ko) 2011-09-21 2020-01-03 상가모 테라퓨틱스, 인코포레이티드 이식 유전자 발현의 조절을 위한 방법 및 조성물
EP2769321B1 (de) 2011-10-21 2016-06-01 Nestec S.A. Verfahren zur verbesserung der diagnose einer entzündlichen darmerkrankung
EP3369818B1 (de) 2011-12-22 2021-06-09 InteRNA Technologies B.V. Mirna zur behandlung von kopf-hals-karzinom
US8841260B2 (en) 2012-02-29 2014-09-23 Sangamo Biosciences, Inc. Methods and compositions for treating Huntington's Disease
US9486540B2 (en) 2012-03-09 2016-11-08 Northeastern University Methods for delivery to the central nervous system of nucleic acid nanoparticles to treat central nervous system disorders
HUE051612T2 (hu) 2012-07-11 2021-03-01 Sangamo Therapeutics Inc Eljárások és készítmények lizoszomális tárolási betegségek kezelésére
JP6329537B2 (ja) 2012-07-11 2018-05-23 サンガモ セラピューティクス， インコーポレイテッド 生物学的薬剤の送達のための方法および組成物
EP2890780B8 (de) 2012-08-29 2020-08-19 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung eines genetischen leidens
ES2824024T3 (es) 2012-10-10 2021-05-11 Sangamo Therapeutics Inc Compuestos modificadores de células T y usos de los mismos
US10201556B2 (en) 2012-11-06 2019-02-12 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
US20150337375A1 (en) 2012-12-21 2015-11-26 The Trustees Of Columbia University In The City Of New York Biomarkers for chronic traumatic encephalopathy
EP2971149B1 (de) 2013-03-15 2018-05-09 Baylor Research Institute Marker für mit colitis ulcerosa (uc) assoziierten kolorektalen neoplasien
US8980864B2 (en) * 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP2016521975A (ja) 2013-05-15 2016-07-28 サンガモ バイオサイエンシーズ， インコーポレイテッド 遺伝的状態の処置のための方法および組成物
WO2015006705A2 (en) 2013-07-11 2015-01-15 The Trustees Of Columbia University In The City Of New York Micrornas that silence tau expression
CA3131284C (en) 2013-08-28 2023-09-19 David Paschon Compositions for linking dna-binding domains and cleavage domains
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
ES2881473T3 (es) 2013-10-17 2021-11-29 Sangamo Therapeutics Inc Métodos de suministro y composiciones para la modificación por ingeniería genética del genoma mediada por nucleasas
CA2929179A1 (en) 2013-11-11 2015-05-14 Sangamo Biosciences, Inc. Htt genetic repressor, viral vector, and uses thereof
HUE044540T2 (hu) 2013-11-13 2019-10-28 Childrens Medical Center Nukleáz közvetítette génexpresszió-szabályozás
EP3068783B1 (de) 2013-11-15 2020-09-23 The Board of Trustees of the Leland Stanford Junior University Agonisten des hypokretin-rezeptors 2 zur verwendung zur behandlung von herzversagen
US10772974B2 (en) 2013-11-18 2020-09-15 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for cardiac regeneration
EP3757116A1 (de) 2013-12-09 2020-12-30 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen für genom-engineering
PT3102673T (pt) 2014-02-03 2020-05-21 Sangamo Biosciences Inc Métodos e composições para tratamento de beta-talassemia
EP3929279A1 (de) 2014-03-18 2021-12-29 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur regulierung der zinkfingerproteinexpression
KR102380324B1 (ko) 2014-05-08 2022-03-30 상가모 테라퓨틱스, 인코포레이티드 헌팅턴병을 치료하기 위한 방법 및 조성물
ES2886012T3 (es) 2014-09-16 2021-12-16 Sangamo Therapeutics Inc Métodos y composiciones para la ingeniería y corrección de genomas mediadas por nucleasas en células madre hematopoyéticas
EP3277823B1 (de) 2015-04-03 2023-09-13 Dana-Farber Cancer Institute, Inc. Zusammensetzung und verfahren zur genomänderung von b-zellen
US10450585B2 (en) 2015-07-13 2019-10-22 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
IL257105B (en) 2015-07-31 2022-09-01 Univ Minnesota Adapted cells and treatment methods
CA2998500A1 (en) 2015-09-23 2017-03-30 Sangamo Therapeutics, Inc. Htt repressors and uses thereof
NZ743429A (en) 2015-12-18 2022-02-25 Sangamo Therapeutics Inc Targeted disruption of the mhc cell receptor
JP7128741B2 (ja) 2015-12-18 2022-08-31 サンガモ セラピューティクス， インコーポレイテッド Ｔ細胞受容体の標的化破壊
BR112018014288A2 (pt) 2016-01-15 2018-12-18 Univ Minnesota métodos e composições para o tratamento de doença neurológica
EP3411056A4 (de) 2016-02-02 2019-10-02 Sangamo Therapeutics, Inc. Zusammensetzungen zur vernetzung von dna-bindungsdomänen und -spaltungsdomänen
MA45670A (fr) 2016-07-13 2019-05-22 Vertex Pharma Procédés, compositions et kits pour augmenter l'efficacité d'édition du génome
SG10201913948PA (en) 2016-08-24 2020-03-30 Sangamo Therapeutics Inc Engineered target specific nucleases
IL264639B2 (en) 2016-08-24 2024-01-01 Sangamo Therapeutics Inc Regulation of globulin gene expression using transgenic nucleases with zinc neurites
US11219695B2 (en) 2016-10-20 2022-01-11 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of Fabry disease
AU2017347928A1 (en) 2016-10-31 2019-05-09 Sangamo Therapeutics, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
CA3043635A1 (en) 2016-12-01 2018-06-07 Sangamo Therapeutics, Inc. Tau modulators and methods and compositions for delivery thereof
JP7416406B2 (ja) 2016-12-08 2024-01-17 ケース ウェスタン リザーブ ユニバーシティ 機能的ミエリン産生を増進させるための方法および組成物
EP4286523A3 (de) 2016-12-20 2024-03-20 Bristol-Myers Squibb Company Verfahren zur verbesserung der effizienz von homologie-gerichteter reparatur (hdr) im zellulären genom
ES2981611T3 (es) 2017-04-28 2024-10-09 Univ Colorado Regents Métodos para tratar la artritis reumatoide mediante el uso de la edición del genoma guiada por ARN del gen de HLA
AU2018256877B2 (en) 2017-04-28 2022-06-02 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
CN111386121A (zh) 2017-10-03 2020-07-07 阿帕塔姆公司 具有抗炎及抗凝血和器官保护性能的核酸分子
CA3079524A1 (en) 2017-11-03 2019-05-09 Interna Technologies B.V. Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
KR20200110687A (ko) 2018-01-17 2020-09-24 버텍스 파마슈티칼스 인코포레이티드 유전체 편집 효율을 증가시키기 위한 퀴녹살리논 화합물, 조성물, 방법 및 키트
WO2019143678A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
WO2019143675A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
US12084655B2 (en) * 2018-04-09 2024-09-10 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
JP2021522828A (ja) 2018-05-06 2021-09-02 エメンドバイオ インコーポレーテッド ヘテロ接合性ｅｌａｎｅ遺伝子の対立遺伝子の差次的ノックアウト
JP2022500052A (ja) 2018-09-18 2022-01-04 サンガモ セラピューティクス， インコーポレイテッド プログラム細胞死１（ｐｄ１）特異的ヌクレアーゼ
WO2020069029A1 (en) 2018-09-26 2020-04-02 Emendobio Inc. Novel crispr nucleases
AU2019361204A1 (en) 2018-10-18 2021-05-27 Intellia Therapeutics, Inc. Compositions and methods for treating alpha-1 antitrypsin deficiencey
WO2020082046A2 (en) 2018-10-18 2020-04-23 Intellia Therapeutics, Inc. Compositions and methods for expressing factor ix
WO2020082041A1 (en) 2018-10-18 2020-04-23 Intellia Therapeutics, Inc. Nucleic acid constructs and methods of use
WO2020082042A2 (en) 2018-10-18 2020-04-23 Intellia Therapeutics, Inc. Compositions and methods for transgene expression from an albumin locus
WO2020112860A1 (en) 2018-11-30 2020-06-04 Intima Bioscience, Inc. Methods of identifying immunomodulatory genes
FI3908568T3 (fi) 2019-01-11 2024-09-13 Acuitas Therapeutics Inc Lipidit aktiivisten aineiden lipidinanohiukkastoimitusta varten
US20220098621A1 (en) 2019-02-05 2022-03-31 Emendobio Inc. Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene
US20220154157A1 (en) 2019-02-06 2022-05-19 Emendobio Inc. New engineered high fidelity cas9
WO2020163017A1 (en) 2019-02-06 2020-08-13 Klogenix Llc Dna binding proteins and uses thereof
KR20210146986A (ko) 2019-04-02 2021-12-06 상가모 테라퓨틱스, 인코포레이티드 베타-지중해빈혈의 치료 방법
CN113950526A (zh) 2019-04-09 2022-01-18 加利福尼亚大学董事会 通过靶向体内表观遗传阻遏实现的持久镇痛
WO2020243485A1 (en) 2019-05-29 2020-12-03 Massachusetts Institute Of Technology Hiv-1 specific immunogen compositions and methods of use
JP7284473B2 (ja) * 2019-06-24 2023-05-31 学校法人東京理科大学 血液成分分離方法及びマイクロ流体デバイスの目詰まり防止剤
CA3159620A1 (en) 2019-11-01 2021-05-06 Sangamo Therapeutics, Inc. Compositions and methods for genome engineering
CA3177093A1 (en) 2020-05-06 2021-11-11 Cellectis S.A. Methods for targeted insertion of exogenous sequences in cellular genomes
CN115715203A (zh) 2020-05-06 2023-02-24 塞勒克提斯公司 对细胞进行基因修饰以递送治疗性蛋白质的方法
EP4182297A1 (de) 2020-07-16 2023-05-24 Acuitas Therapeutics, Inc. Kationische lipide zur verwendung in lipidnanopartikeln
US20220064596A1 (en) 2020-08-25 2022-03-03 Kite Pharma, Inc. T cells with improved functionality
WO2022243565A1 (en) 2021-05-21 2022-11-24 Cellectis S.A. Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
WO2023070072A1 (en) 2021-10-21 2023-04-27 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Retroelement-generated transcription factor decoys
WO2023081756A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
IL313486A (en) 2021-12-16 2024-08-01 Acuitas Therapeutics Inc Lipids for use in lipid nanoparticle formulations
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023183589A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Rt-dna fidelity and retron genome editing
WO2023183627A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
WO2023183588A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods of assessing engineered retron activity, and uses thereof
WO2023196725A1 (en) 2022-04-07 2023-10-12 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Continuous multiplexed phage genome engineering using a retron editing template
WO2024003334A1 (en) 2022-06-30 2024-01-04 Cellectis S.A. Enhancing safety of t-cell-mediated immunotherapy
WO2024044673A1 (en) 2022-08-24 2024-02-29 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Dual cut retron editors for genomic insertions and deletions
WO2024094775A1 (en) 2022-11-03 2024-05-10 Cellectis S.A. Enhancing efficacy and safety of t-cell-mediated immunotherapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120657A (en) * 1986-12-05 1992-06-09 Agracetus, Inc. Apparatus for genetic transformation
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5149782A (en) * 1988-08-19 1992-09-22 Tanox Biosystems, Inc. Molecular conjugates containing cell membrane-blending agents
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5122466A (en) * 1989-06-13 1992-06-16 North Carolina State University Ballistic transformation of conifers
WO1992019749A1 (en) * 1991-05-03 1992-11-12 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Targeted delivery of genes encoding cell surface receptors
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
JP4285766B2 (ja) * 1994-03-23 2009-06-24 オハイオ ユニバーシティ 緻密にした核酸および細胞へのデリバリ
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells

Also Published As

Publication number Publication date
AU696455C (en) 2006-03-02
JP2009114193A (ja) 2009-05-28
AU696455B2 (en) 1998-09-10
JPH10503469A (ja) 1998-03-31
US5972900A (en) 1999-10-26
CA2186118A1 (en) 1995-09-28
US5877302A (en) 1999-03-02
DE69535853D1 (de) 2008-11-20
WO1995025809A1 (en) 1995-09-28
ES2316148T3 (es) 2009-04-01
EP0752005B1 (de) 2008-10-08
US6008336A (en) 1999-12-28
JP4285766B2 (ja) 2009-06-24
EP0752005A1 (de) 1997-01-08
CA2186118C (en) 2010-10-19
AU2127695A (en) 1995-10-09

Similar Documents

Publication Publication Date Title
ATE410518T1 (de) Kompaktnukleinsäure und ihre verabreichung in zellen
FI963103A0 (fi) Ei-virusvektori
CA2098849A1 (en) Control of gene expression by ionizing radiation
WO2001030965A3 (en) Methods of in vivo gene transfer using a sleeping beauty transposon system
DE69535576D1 (de) Zusammensetzungen von nucleinsäure und viskosität-erhöhendem polymer pvp, zur verwendung in gentherapie
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
DE69534669D1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
HUP9801207A2 (hu) Nukleinsavat tartalmazó készítmények, előállításuk és alkalmazásuk
ATE237312T1 (de) In liposomen verkapselte nukleinsäurekomplexe
PT801649E (pt) Derivados de hidroxilamina uteis para aumentar a producao de proteinas moleculares adventicias e sua preparacao
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
ES2156421T3 (es) Composiciones utiles para la transferencia de polinucleotidos terapeuticamente activos a una celula diana y su utilizacion en la terapia genica.
AU5161800A (en) Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
HUP0004728A1 (hu) Javított eljárás nukleinsav bevitelére többsejtes eukarióta szervezet sejtjeibe és kombinált alkalmazása
CA2019676A1 (en) Particle-mediated transformation of animal somatic cells
IL112665A0 (en) 5-substituted derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
ATE199645T1 (de) Kombination von nekrose-induzierenden substanzen mit substanzen, die durch nekrosen aktiviert werden, zur selektiven therapie von tumoren und entzündlichen erkrankungen
ATE445417T1 (de) Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung
BR0206347A (pt) Conjugados de compostos de macrolìdeo especìficos a células imunes com compostos antiinflamatórios para objetivação celular aperfeiçoada de terapia antiinflamatória
PT912185E (pt) Novas formulacoes farmaceuticas contendo derivados de ester nitrato de esteroides proveitosos como farmacos anti-inflamatorios
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
HK1023942A1 (en) Self-regulated apoptosis of inflammatory by gene therapy
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
US5137820A (en) Superoxide dismutase derivatives, a method of producing the same and medicinal uses of the same
PT1124577E (pt) Utilizacao de uma proteina ompa de enterobacteria para o direccionamento especifico para as celulas apresentadoras de antigenios

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties